Asciminib: all 29 studies that test it

Page 1 of 1. Open to participants first (13), then studies with results posted, then the rest; newest registration first within each.

• Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CPRecruitingNCT07354074Phase 2
• Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALLRecruitingNCT07250087Phase 1
• Asciminib in HER2+ Breast Cancer Brain MetastasesRecruitingNCT07136428Phase 1/2
• Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaRecruitingNCT07040982Phase 1
• Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid LeukemiaRecruitingNCT06629584Phase 2
• Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.RecruitingNCT06514534Phase 2
• A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid LeukemiaRecruitingNCT06368414Phase 2
• Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaRecruitingNCT06308588Phase 1/2
• Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.RecruitingNCT06236724Phase 2
• Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid LeukemiaRecruitingNCT04925479Phase 1/2
• Asciminib Roll-over StudyRecruitingNCT04877522Phase 4
• Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI DiscontinuationRecruitingNCT04838041Phase 2
• ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CMLRecruitingNCT03595917Phase 1
• A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)Active, not recruitingNCT05456191Phase 3Results posted
• A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPActive, not recruitingNCT04971226Phase 3Results posted
• Asciminib Treatment Optimization in ≥ 3rd Line CML-CPCompletedNCT04948333Phase 3Results posted
• Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I MutationCompletedNCT04666259Phase 3Results posted
• ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase InhibitorTerminatedNCT04216563Phase 2Results posted
• Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.CompletedNCT03578367Phase 2Results posted
• Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIsCompletedNCT03106779Phase 3Results posted
• Efficacy of Asciminib in Chronic Phase CML Patients With T315I MutationsActive, not recruitingNCT07789574Phase 2
• Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I MutationCompletedNCT06427811Phase 4
• Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CMLTerminatedNCT05413915Phase 3
• Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous LeukemiaActive, not recruitingNCT05384587Phase 2
• Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic PhaseActive, not recruitingNCT05143840Phase 2
• Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase InhibitorsCompletedNCT04795427Phase 2
• A Study of Full Treatment-free Remission in Patients With Chronic Myeloid LeukemiaTerminatedNCT03874858Phase 2
• Pharmacokinetics Study of Asciminib in Subjects With Impaired Renal Function Compared to Matched Healthy VolunteersCompletedNCT03605277Phase 1
• A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired SubjectsCompletedNCT02857868Phase 1

← Asciminib overview